Paul C. Grimm
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Paul C. Grimm has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
David N. Rush
5 shared publicationsJohn Jeffery
4 shared publicationsJim Gough
3 shared publications- Peter Nickerson
Department of Medicine, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB, Canada
3 shared publications Elzbieta Stern
2 shared publicationsRachel M. McKenna
2 shared publications
Latest Publications
- 1 August 2006
- Published by Wiley in Pediatric Transplantation
- Vol. 10 (5) , 533-535
Use of an immune function assay to monitor immunosuppression
- 1 August 2006
- Published by Wiley in Pediatric Transplantation
- Vol. 10 (5) , 533-535
Use of an immune function assay to monitor immunosuppression
- 1 June 2006
- Published by Wiley in Evidence-Based Child Health: A Cochrane Review Journal
- Vol. 1 (2) , 588-589
Commentary on ‘Antibiotics for acute pyelonephritis in children’
- 1 June 2006
- Published by Wiley in Evidence-Based Child Health: A Cochrane Review Journal
- Vol. 1 (2) , 588-589
Commentary on ‘Antibiotics for acute pyelonephritis in children’
- 1 February 2004
- Published by Wiley in Pediatric Transplantation
- Vol. 8 (1) , 3-5
The protocol renal allograft biopsy: Has its time come?
- 1 February 2004
- Published by Wiley in Pediatric Transplantation
- Vol. 8 (1) , 3-5
The protocol renal allograft biopsy: Has its time come?
- 1 June 2003
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 14 (6) , 1662-1668
Computerized Image Analysis of Sirius Red–Stained Renal Allograft Biopsies as a Surrogate Marker to Predict Long-Term Allograft Function
Chronic allograft nephropathy (CAN) is a major problem in posttransplant management. The lack of a reliable and early surrogate marker of CAN has hampered patient care and research. In this study, the Cortical Fractional Interstitial Fibrosis Volume (VIntFib), quantitated with computerized image analysis of Sirius Red–stained protocol biopsies, was examined as a potential surrogate for time to graft failure (TTGF) in 68 renal allograft recipients. At 6 mo posttransplant, VIntFib was highly correlated with TTGF (r = 0.64, P < 0.001). Both the Banff Chronic Sum and the Acute Sum Scores were also correlated with TTGF, but less strongly (r = 0.28, P < 0.02; r = 0.35, P < 0.003, respectively). As VIntFib was not correlated with the Banff Chronic Score, a multivariate model was created that incorporated VIntFib and both Acute and Chronic Banff pathology. This model was highly correlated with TTGF (r = 0.7, P < 0.0001). These findings suggest that VIntFib determined by computerized image analysis of Sirius Red–stained protocol biopsies at 6 mo posttransplant, with or without incorporation of Banff acute and chronic scoring, may provide an early surrogate for time to graft failure in renal allograft recipients. E-mail: pgrimm@ucsd.edu
- 1 June 2003
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 14 (6) , 1662-1668
Computerized Image Analysis of Sirius Red–Stained Renal Allograft Biopsies as a Surrogate Marker to Predict Long-Term Allograft Function
Chronic allograft nephropathy (CAN) is a major problem in posttransplant management. The lack of a reliable and early surrogate marker of CAN has hampered patient care and research. In this study, the Cortical Fractional Interstitial Fibrosis Volume (VIntFib), quantitated with computerized image analysis of Sirius Red–stained protocol biopsies, was examined as a potential surrogate for time to graft failure (TTGF) in 68 renal allograft recipients. At 6 mo posttransplant, VIntFib was highly correlated with TTGF (r = 0.64, P < 0.001). Both the Banff Chronic Sum and the Acute Sum Scores were also correlated with TTGF, but less strongly (r = 0.28, P < 0.02; r = 0.35, P < 0.003, respectively). As VIntFib was not correlated with the Banff Chronic Score, a multivariate model was created that incorporated VIntFib and both Acute and Chronic Banff pathology. This model was highly correlated with TTGF (r = 0.7, P < 0.0001). These findings suggest that VIntFib determined by computerized image analysis of Sirius Red–stained protocol biopsies at 6 mo posttransplant, with or without incorporation of Banff acute and chronic scoring, may provide an early surrogate for time to graft failure in renal allograft recipients. E-mail: pgrimm@ucsd.edu
- 12 July 2001
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 345 (2) , 93-97
Neointimal and Tubulointerstitial Infiltration by Recipient Mesenchymal Cells in Chronic Renal-Allograft Rejection
Tissue remodeling depends on mesenchymal cells (fibroblasts and myofibroblasts) and is a prominent feature of chronic renal-transplant rejection. It is not known whether the mesenchymal cells that participate in remodeling originate locally or from circulating precursor cells. We obtained biopsy specimens of renal allografts from six male recipients of an allograft from a female donor, four female recipients of an allograft from a male donor, two male recipients of an allograft from a male donor, and two female recipients of an allograft from a female donor. All the allografts were undergoing chronic rejection. We used immunohistochemical methods to identify mesenchymal cells with smooth-muscle α-actin and in situ hybridization to identify mesenchymal cells with Y-chromosome DNA. No Y-chromosome bodies were identified in the case of the two renal-allograft specimens in which both the donor and the recipient were female. In the case of the two renal-allograft specimens in which both the donor and the recipient were male, approximately 40 percent of mesenchymal cells contained a Y-chromosome body. In the case of the six specimens in which the donor was female and the recipient was male, a mean (±SD) of 34±16 percent of mesenchymal cells in the neointima, 38±12 percent of such cells in the adventitia, and 30±7 percent of such cells in the interstitium contained the Y-chromosomal marker, indicating that they originated from the recipient rather than the donor. In the case of the four renal-allograft specimens in which the donor was male and the recipient was female, the respective values were 24±15 percent, 33±9 percent, and 23±8 percent, indicating a persistent population of donor mesenchymal cells. The presence of mesenchymal cells of host origin in the vascular and interstitial compartments of renal allografts undergoing chronic rejection provides evidence that a circulating mesenchymal precursor cell has the potential to migrate to areas of inflammation.
- 12 July 2001
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 345 (2) , 93-97
Neointimal and Tubulointerstitial Infiltration by Recipient Mesenchymal Cells in Chronic Renal-Allograft Rejection
Tissue remodeling depends on mesenchymal cells (fibroblasts and myofibroblasts) and is a prominent feature of chronic renal-transplant rejection. It is not known whether the mesenchymal cells that participate in remodeling originate locally or from circulating precursor cells. We obtained biopsy specimens of renal allografts from six male recipients of an allograft from a female donor, four female recipients of an allograft from a male donor, two male recipients of an allograft from a male donor, and two female recipients of an allograft from a female donor. All the allografts were undergoing chronic rejection. We used immunohistochemical methods to identify mesenchymal cells with smooth-muscle α-actin and in situ hybridization to identify mesenchymal cells with Y-chromosome DNA. No Y-chromosome bodies were identified in the case of the two renal-allograft specimens in which both the donor and the recipient were female. In the case of the two renal-allograft specimens in which both the donor and the recipient were male, approximately 40 percent of mesenchymal cells contained a Y-chromosome body. In the case of the six specimens in which the donor was female and the recipient was male, a mean (±SD) of 34±16 percent of mesenchymal cells in the neointima, 38±12 percent of such cells in the adventitia, and 30±7 percent of such cells in the interstitium contained the Y-chromosomal marker, indicating that they originated from the recipient rather than the donor. In the case of the four renal-allograft specimens in which the donor was male and the recipient was female, the respective values were 24±15 percent, 33±9 percent, and 23±8 percent, indicating a persistent population of donor mesenchymal cells. The presence of mesenchymal cells of host origin in the vascular and interstitial compartments of renal allografts undergoing chronic rejection provides evidence that a circulating mesenchymal precursor cell has the potential to migrate to areas of inflammation.
- 1 November 1999
- Published by Wiley in Pediatric Transplantation
- Vol. 3 (4) , 257-270
Quantitation of allograft fibrosis and chronic allograft nephropathy
Despite improvements in the prevention and treatment of acute renal allograft rejection, the long‐term survival of renal transplants has not increased. Immunologic and non‐immunologic factors contribute to the gradual deterioration of graft function and to the histologic lesion characterized by vascular and interstitial fibrosis (‘chronic rejection’). Quantitation of this process has been attempted using various invasive and non‐invasive methods. These methods, performed at different times post‐transplant, are reviewed in this article. In particular, pathology scoring systems and the potential of using computerized image analysis of biopsy material are discussed.
- 1 November 1999
- Published by Wiley in Pediatric Transplantation
- Vol. 3 (4) , 257-270
Quantitation of allograft fibrosis and chronic allograft nephropathy
Despite improvements in the prevention and treatment of acute renal allograft rejection, the long‐term survival of renal transplants has not increased. Immunologic and non‐immunologic factors contribute to the gradual deterioration of graft function and to the histologic lesion characterized by vascular and interstitial fibrosis (‘chronic rejection’). Quantitation of this process has been attempted using various invasive and non‐invasive methods. These methods, performed at different times post‐transplant, are reviewed in this article. In particular, pathology scoring systems and the potential of using computerized image analysis of biopsy material are discussed.
- 1 July 1999
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 10 (7) , 1582-1589
Clinical Rejection Is Distinguished from Subclinical Rejection by Increased Infiltration by a Population of Activated Macrophages
: It has been reported previously that one-third of protocol renal biopsies in asymptomatic, biochemically stable renal transplant recipients in the first 6 mo show unsuspected subclinical graft rejection (both infiltrate and tubulitis) and that subclinical rejection is a risk factor for chronic renal dysfunction. This study was performed to determine whether differences in phenotype or activation status of graft-infiltrating cells underlie these different manifestations of acute rejection. Biopsies with normal histology (n = 10), subclinical rejection (n = 13), and clinical rejection (n = 9) were studied using immunohistochemistry and computerized image analysis. Subclinical and clinical rejections had similar histologic Banff scores. Univariate analysis showed a trend for a higher infiltration with CD8+ (P = 0.053) and CD68+ (P = 0.06) cells in clinical rejection. Of the activation markers studied (CD25, perforin, tumor necrosis factor-α), only allograft inflammatory factor-1 +-activated macrophages were significantly (P = 0.014) increased in the infiltrate of clinical rejection biopsies. These data suggest that activated macrophages or their products are responsible for acute renal dysfunction associated with clinical rejection episodes.
- 1 July 1999
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 10 (7) , 1582-1589
Clinical Rejection Is Distinguished from Subclinical Rejection by Increased Infiltration by a Population of Activated Macrophages
: It has been reported previously that one-third of protocol renal biopsies in asymptomatic, biochemically stable renal transplant recipients in the first 6 mo show unsuspected subclinical graft rejection (both infiltrate and tubulitis) and that subclinical rejection is a risk factor for chronic renal dysfunction. This study was performed to determine whether differences in phenotype or activation status of graft-infiltrating cells underlie these different manifestations of acute rejection. Biopsies with normal histology (n = 10), subclinical rejection (n = 13), and clinical rejection (n = 9) were studied using immunohistochemistry and computerized image analysis. Subclinical and clinical rejections had similar histologic Banff scores. Univariate analysis showed a trend for a higher infiltration with CD8+ (P = 0.053) and CD68+ (P = 0.06) cells in clinical rejection. Of the activation markers studied (CD25, perforin, tumor necrosis factor-α), only allograft inflammatory factor-1 +-activated macrophages were significantly (P = 0.014) increased in the infiltrate of clinical rejection biopsies. These data suggest that activated macrophages or their products are responsible for acute renal dysfunction associated with clinical rejection episodes.
- 1 February 1995
- Published by Wolters Kluwer Health in Transplantation
- Vol. 59 (4) , 579-584
LOW FREQUENCY OF INFILTRATING CELLS INTENSELY EXPRESSING T CELL CYTOKINE mRNA IN HUMAN RENAL ALLOGRAFT REJECTION1,2
- 1 February 1995
- Published by Wolters Kluwer Health in Transplantation
- Vol. 59 (4) , 579-584
LOW FREQUENCY OF INFILTRATING CELLS INTENSELY EXPRESSING T CELL CYTOKINE mRNA IN HUMAN RENAL ALLOGRAFT REJECTION1,2